...
首页> 外文期刊>Bioorganic and medicinal chemistry >Amine-free melanin-concentrating hormone receptor 1 antagonists: Novel 1-(1H-benzimidazol-6-yl)pyridin-2(1H)-one derivatives and design to avoid CYP3A4 time-dependent inhibition
【24h】

Amine-free melanin-concentrating hormone receptor 1 antagonists: Novel 1-(1H-benzimidazol-6-yl)pyridin-2(1H)-one derivatives and design to avoid CYP3A4 time-dependent inhibition

机译:无胺的黑色素浓缩激素受体1拮抗剂:新型1-(1H-苯并咪唑-6-基)吡啶2-2(1H)-一衍生物和避免CYP3A4时间依赖性抑制的设计

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Melanin-concentrating hormone (MCH) is an attractive target for antiobesity agents, and numerous drug discovery programs are dedicated to finding small-molecule MCH receptor 1 (MCHR1) antagonists. We recently reported novel pyridine-2(1H)-ones as aliphatic amine-free MCHR1 antagonists that structurally featured an imidazo[1,2-a] pyridine-based bicyclic motif. To investigate imidazopyridine variants with lower basicity and less potential to inhibit cytochrome P450 3A4 (CYP3A4), we designed pyridine2( 1H)-ones bearing various less basic bicyclic motifs. Among these, a lead compound 6a bearing a 1H-benzimidazole motif showed comparable binding affinity to MCHR1 to the corresponding imidazopyridine derivative 1. Optimization of 6a afforded a series of potent thiophene derivatives (6q-u); however, most of these were found to cause time-dependent inhibition (TDI) of CYP3A4. As bioactivation of thiophenes to form sulfoxide or epoxide species was considered to be a major cause of CYP3A4 TDI, we introduced electron withdrawing groups on the thiophene and found that a CF3 group on the ring or a Cl adjacent to the sulfur atom helped prevent CYP3A4 TDI. Consequently, 4-[(5-chlorothiophen-2-yl) methoxy]-1-(2-cyclopropyl-1-methyl-1H-benzimidazol-6-yl)pyridin-2(1H)-one (6s) was identified as a potent MCHR1 antagonist without the risk of CYP3A4 TDI, which exhibited a promising safety profile including low CYP3A4 inhibition and exerted significant antiobesity effects in diet-induced obese F344 rats. (C) 2016 Elsevier Ltd. All rights reserved.
机译:黑色素浓缩激素(MCH)是抗肥胖药的诱人靶标,许多药物发现计划致力于发现小分子MCH受体1(MCHR1)拮抗剂。我们最近报道了新型吡啶2(1H)-作为无脂肪胺的MCHR1拮抗剂,其结构上具有基于咪唑并[1,2-a]吡啶的双环基序。若要研究具有较低的碱性和较低的抑制细胞色素P450 3A4(CYP3A4)潜力的咪唑并吡啶变体,我们设计了带有各种较少碱性双环基序的吡啶2(1H)-。其中,带有1H-苯并咪唑基序的先导化合物6a对MCHR1与相应的咪唑并吡啶衍生物1表现出可比的结合亲和力。6a的优化得到了一系列有效的噻吩衍生物(6q-u);然而,发现其中大多数导致CYP3A4的时间依赖性抑制(TDI)。由于噻吩的生物活化作用形成亚砜或环氧化物物种被认为是CYP3A4 TDI的主要原因,我们在噻吩上引入了吸电子基团,发现环上的CF3基团或与硫原子相邻的Cl有助于防止CYP3A4 TDI 。因此,鉴定出4-[(5-氯噻吩-2-基)甲氧基] -1-(2-环丙基-1-甲基-1H-苯并咪唑-6-基)吡啶-2(1H)-(6s)为一种有效的MCHR1拮抗剂,无CYP3A4 TDI风险,在饮食诱导的肥胖F344大鼠中表现出良好的安全性,其中包括低CYP3A4抑制作用,并具有显着的抗肥胖作用。 (C)2016 Elsevier Ltd.保留所有权利。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号